Stumpf U, Schmidmaier R, Taipaleenmaki H, Bocker W, Kurth A, Hesse E
Z Rheumatol. 2025; 84(2):107-112.
PMID: 39806104
DOI: 10.1007/s00393-024-01610-y.
Tholen P, Brown C, Keil C, Bayir A, Zeng H, Haase H
Mol Syst Des Eng. 2023; 7(11):1415-1421.
PMID: 37927331
PMC: 10624163.
DOI: 10.1039/d2me00185c.
Park S, Yoo J, Ahn M
Pharmaceuticals (Basel). 2023; 16(10).
PMID: 37895975
PMC: 10610495.
DOI: 10.3390/ph16101504.
Gisbert-Garzaran M, Gomez-Cerezo M, Vallet-Regi M
Int J Mol Sci. 2023; 24(3).
PMID: 36768328
PMC: 9916506.
DOI: 10.3390/ijms24032007.
Iolascon G, Moretti A
Int J Mol Sci. 2022; 23(13).
PMID: 35805927
PMC: 9267106.
DOI: 10.3390/ijms23136921.
Engineered osteoclasts resorb necrotic alveolar bone in anti-RANKL antibody-treated mice.
Buranaphatthana W, Yavirach A, Leaf E, Scatena M, Zhang H, An J
Bone. 2021; 153:116144.
PMID: 34375732
PMC: 8555912.
DOI: 10.1016/j.bone.2021.116144.
Smart Cargo Delivery System based on Mesoporous Nanoparticles for Bone Disease Diagnosis and Treatment.
Pan P, Yue Q, Li J, Gao M, Yang X, Ren Y
Adv Sci (Weinh). 2021; 8(12):e2004586.
PMID: 34165902
PMC: 8224433.
DOI: 10.1002/advs.202004586.
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A, Carlino F, Giunta E, Franzese E, Guerrera L, Lauro V
Curr Treat Options Oncol. 2021; 22(5):45.
PMID: 33864145
PMC: 8052225.
DOI: 10.1007/s11864-021-00835-2.
The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women.
Rouach V, Goldshtein I, Buch A, Catane R, Chodick G, Stern N
J Bone Oncol. 2019; 16:100202.
PMID: 31334001
PMC: 6616345.
DOI: 10.1016/j.jbo.2018.10.001.
Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis.
Shi J, Liang G, Huang R, Liao L, Qin D
J Orthop Surg Res. 2018; 13(1):225.
PMID: 30180868
PMC: 6123982.
DOI: 10.1186/s13018-018-0918-7.
New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.
Fernandez D, Ramis R, Ortega-Castro J, Casasnovas R, Vilanova B, Frau J
J Comput Aided Mol Des. 2017; 31(7):675-688.
PMID: 28631130
DOI: 10.1007/s10822-017-0034-5.
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Popp A, Senn R, Curkovic I, Senn C, Buffat H, Popp P
Osteoporos Int. 2017; 28(6):1995-2002.
PMID: 28299378
DOI: 10.1007/s00198-017-3992-5.
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au K, Satterlee A, Min Y, Tian X, Kim Y, Caster J
Biomaterials. 2016; 82:178-93.
PMID: 26763733
PMC: 4728024.
DOI: 10.1016/j.biomaterials.2015.12.018.
Effect of bisphosphonates on orthodontic tooth movement-an update.
Krishnan S, Pandian S, S A
J Clin Diagn Res. 2015; 9(4):ZE01-5.
PMID: 26023659
PMC: 4437175.
DOI: 10.7860/JCDR/2015/11162.5769.
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
Amodio N, Rossi M, Raimondi L, Pitari M, Botta C, Tagliaferri P
Oncotarget. 2015; 6(15):12837-61.
PMID: 25968566
PMC: 4536984.
DOI: 10.18632/oncotarget.3805.
Osteochemonecrosis: an overview.
Hellstein J
Head Neck Pathol. 2014; 8(4):482-90.
PMID: 25409847
PMC: 4245410.
DOI: 10.1007/s12105-014-0583-z.
Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.
Songpatanasilp T, Mumtaz M, Chhabra H, Yu M, Sorsaburu S
Singapore Med J. 2014; 55(9):493-501.
PMID: 25273935
PMC: 4293947.
DOI: 10.11622/smedj.2014120.
The protocol for the isolation and cryopreservation of osteoclast precursors from mouse bone marrow and spleen.
Boraschi-Diaz I, Komarova S
Cytotechnology. 2014; 68(1):105-114.
PMID: 25245056
PMC: 4698259.
DOI: 10.1007/s10616-014-9759-3.
Impact of Bisphosphonate on Orthodontic tooth movement and osteoclastic count: An Animal Study.
Venkataramana V, Chidambaram S, Reddy B, Goud E, Arafath M, Krishnan6 S
J Int Oral Health. 2014; 6(2):1-8.
PMID: 24876695
PMC: 4037805.
Bisphophonates in CKD patients with low bone mineral density.
Liu W, Yen J, Lang C, Yan M, Lu K
ScientificWorldJournal. 2014; 2013:837573.
PMID: 24501586
PMC: 3899701.
DOI: 10.1155/2013/837573.